Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
Rizos CV, Elisaf MS, Skoumas I, Tziomalos K, Kotsis V, Rallidis L, Garoufi A, Athyros VG, Skalidis E, Kolovou G, Koutagiar I, Papagianni M, Antza C, Katsiki N, Ganotakis E, Liberopoulos EN. Rizos CV, et al. Among authors: skoumas i. Atherosclerosis. 2018 Oct;277:308-313. doi: 10.1016/j.atherosclerosis.2018.08.017. Atherosclerosis. 2018. PMID: 30270064
Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women.
Athyros VG, Ganotakis E, Kolovou GD, Nicolaou V, Achimastos A, Bilianou E, Alexandrides T, Karagiannis A, Paletas K, Liberopoulos EN, Tziomalos K, Petridis D, Kakafika A, Elisaf MS, Mikhailidis DP; Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative. Athyros VG, et al. Curr Vasc Pharmacol. 2011 Nov;9(6):647-57. doi: 10.2174/157016111797484080. Curr Vasc Pharmacol. 2011. PMID: 21476961 Clinical Trial.
Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Achimastos A, Alexandrides T, Alexopoulos D, Athyros V, Bargiota A, Bilianou E, Chrysochoou C, Drogari E, Elisaf M, Ganotakis E, Goudevenos I, Ioannidis I, Kolovou G, Kotsis V, Lekakis I, Liberopoulos E, Melidonis A, Nikolaou V, Ntaios G, Papanas N, Pappas S, Pitsavos C, Rallidis L, Richter D, Skoumas I, Tentolouris N, Tousoulis D, Tselepis A, Tsioufis K, Tziakas D, Tziomalos K, Vardas P, Vlachopoulos C, Vlahakos D. Achimastos A, et al. Among authors: skoumas i. Hormones (Athens). 2016 Jan-Mar;15(1):8-14. doi: 10.14310/horm.2002.1659. Hormones (Athens). 2016. PMID: 27086681 Free article.
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Sabatine MS, et al. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304224 Free article. Clinical Trial.
64 results